Azienda Ospedaliero Universitaria Policlinico G Rodolico San Marco Di Catania
- Address
- lock Available on a paid plan
Skin and Connective Tissue Diseases
The department focuses on systemic sclerosis-associated interstitial lung disease, aiming to assess new treatments that may slow lung function decline and improve quality of life.
- Evaluation of belimumab as an adjunct therapy
- Measurement of forced vital capacity changes
- Comparison with standard care
Research at the Azienda Ospedaliero Universitaria Policlinico G Rodolico San Marco Di Catania supports advances in managing this rare connective‑tissue disorder.
Nutritional and Metabolic Diseases
Studies target exocrine pancreatic insufficiency, investigating the safety of novel lipase formulations to enhance digestive enzyme replacement.
- Safety profiling of NHS7108
- Assessment of nutrient absorption efficiency
- Comparison with existing pancrelipase therapy
The site’s work contributes to better nutritional support for patients with pancreatic enzyme deficits.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliero Universitaria Policlinico G Rodolico San Marco Di Catania
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Subcutaneous Belimumab in Systemic Sclerosis-Associated Interstitial Lung Disease: A Randomized, Double-Blind, Placebo-Controlled Study | Glaxosmithkline Research & Development Limited | Phase IV | Recruiting | May 2024 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amylase | 1 | Unknown | 2026-06-29 | 2026-06-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.